According to the FDA's press release it agreed to approve the drug for obesity based on three randomised, double-blind, placebo-controlled trials during which more than 2,600 patients received Wegovy for up to 68 weeks and more than 1,500 patients received placebo (US FDA 2021)
This extended half-life supports long-lasting effects, making it a convenient option for patients who struggle with daily medication regimens
These reports may reflect individual variation, concurrent factors such as rapid weight loss (which can affect skin integrity), nutritional changes, or coincidental dermatological conditions rather than a direct drug effect
FDA-Approved vs
I hope you can use this information to consider whether or not these drugs are right for you
Antibody development means the immune system has created specific proteins that recognize and bind to tirzepatide